查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1888778

美國藥局市場規模、佔有率和趨勢分析報告：按產品類型、所有權和細分市場分類的預測（2025-2033 年）

U.S. Pharmacy Market Size, Share & Trends Analysis Report By Product Type (Prescription, OTC), By Type (Hospital Pharmacy, Retail Chains, ePharmacy), By Ownership, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國藥局市場規模及趨勢：

2024年美國藥局市場規模估計為7,324.4億美元，預計到2033年將達到17,070.2億美元。

預計從 2025 年到 2033 年，該行業將以 9.91% 的複合年成長率成長。這一成長歸因於慢性病的增加、處方藥的高使用率以及該國老年人口的成長。

美國心臟協會 (AHA) 2023 年的一份報告顯示，近一半 (48.6%) 的美國患有某種形式的心血管疾病，包括心臟疾病、心臟衰竭、中風或高血壓。

目錄

第1章 調查範圍與調查方法

第2章執行摘要

第3章美國藥局市場－產業展望

  • 市場體系展望
  • 市場動態
  • 法規環境和報銷前景
  • 商業環境分析工具

第4章：美國藥局市場：依產品類型分類的估算與趨勢分析

  • 按產品類型分類的差異分析和市場佔有率分析（2024 年和 2033 年）
  • 美國藥局市場規模及預測，依產品類型分類的預測
    • 處方藥
    • 非處方藥

第5章：美國藥局市場：按類型分類的估算與趨勢分析

  • 按類型分類的變異分析和市場佔有率分析（2024 年和 2033 年）
  • 美國藥局市場規模及按類型分類的預測，2021-2033年
  • 美國藥房市場：按類型分類的藥房估計值（2021-2033 年）
  • 美國藥房市場：按類型處方箋量預測（2021-2033 年）
  • 美國藥局市場：按服務區域分類的預計處方箋量，2024 年（%）
  • 美國藥局市場：處方箋量預測（以處方箋計），2024 年（%）
    • 零售連鎖店
    • 超級市場藥房
    • 醫療保健系統/醫院藥房
    • 獨立藥房
    • 郵購藥房
    • 專科藥房/中央配藥房
    • 長期護理和國防藥房
    • 網路藥局
    • 其他

第6章美國藥局市場競爭分析

  • 公司分類
  • 2024年企業市場占有率預測分析
    • CVS Pharmacy
    • Walgreens Boots Alliance, Inc.
    • Scriptco Pharmacy
    • Walmart Pharmacy
    • Avita Pharmacy
    • The Kroger Co.
    • Albertsons Companies, Inc.
    • Costco Wholesale Corporation.
    • Sam's West, Inc.
Product Code: GVR-4-68040-044-6

U.S. Pharmacy Market Size & Trends:

The U.S. pharmacy market size was estimated at USD 732.44 billion in 2024 and is projected to reach at USD 1,707.02 billion by 2033, growing at a CAGR of 9.91% from 2025 to 2033. The growth is attributed to the rising prevalence of chronic diseases, the high utilization of prescription drugs, and the increasing elderly population in the country.

A report from the 2023 American Heart Association (AHA) indicates that nearly half of the U.S. population (48.6%) has some form of cardiovascular disease, including coronary heart disease, heart failure, stroke, and high blood pressure.

U.S. Pharmacy Market Report Segmentation

This report forecasts revenue growth, country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. pharmacy market report based on type, product type, and ownership.

  • Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Retail chains (e.g., Walgreens, CVS)
  • Supermarket pharmacies
  • Health system/hospital pharmacies
  • Independent pharmacies
  • Mail-order pharmacies
  • Specialty / central fill pharmacies
  • Long-term care and defense-related pharmacies
  • ePharmacy
  • Others
  • Product Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Prescription
  • OTC
  • Ownership Outlook (Revenue, USD Billion, 2021 - 2033)
  • Chain
  • Independent

Table of Contents

Chapter 1. Report Scope & Research Methodology

  • 1.1 Market Segmentation
    • 1.1.1 Segment Definition
      • 1.1.1.1 Product Type
      • 1.1.1.2 Type
  • 1.2 Estimates and Forecast Timeline
  • 1.3 Research Methodology
    • 1.3.1 Information Procurement
    • 1.3.2 Purchased Database
    • 1.3.3 Gvr's Internal Database
    • 1.3.4 Secondary Sources
    • 1.3.5 Primary Research
    • 1.3.6 Details Of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Three Pillars of Market Estimation
      • 1.6.1.1 Secondary Market Research
      • 1.6.1.2 Primary Market Intelligence
        • 1.6.1.2.1 In-Depth Interviews (IDIs)
        • 1.6.1.2.2 Online Survey Program
    • 1.6.2 Market Modeling & Forecasting
      • 1.6.2.1 Model 1: Volume-Price Analysis
        • 1.6.2.1.1 Step 1: Prescription volume estimation
        • 1.6.2.1.2 Channel-Wise Methodology
          • 1.6.2.1.2.1 Retail Chains (CVS, Walgreens, etc.)
          • 1.6.2.1.2.2 Supermarket Pharmacies (Kroger, Albertsons, Publix)
          • 1.6.2.1.2.3 Health System / Hospital Outpatient Pharmacies
          • 1.6.2.1.2.4 Independent Pharmacies
          • 1.6.2.1.2.5 Mail-Order Pharmacies
          • 1.6.2.1.2.6 Specialty / Central Fill Pharmacies
          • 1.6.2.1.2.7 Long-Term Care (LTC) and Defense-Related Pharmacies
          • 1.6.2.1.2.8 ePharmacies (Amazon, Capsule, Hims & Hers, etc.)
          • 1.6.2.1.2.9 Other Channels
          • 1.6.2.1.2.10 Aggregation & Triangulation
        • 1.6.2.1.3 Step 2: Determining Average Realized Price (ARP)
        • 1.6.2.1.4 Step 2: OTC Revenue
      • 1.6.2.2 Model 2: Company Market Share Analysis
        • 1.6.2.2.1 Step 1: Public Filings
        • 1.6.2.2.2 Step 2: Private & Independent Estimates
        • 1.6.2.2.3 Step 3: Market Share Allocation
      • 1.6.2.3 CAGR/Forecasting Calculations & Assumptions
        • 1.6.2.3.1 Key Forecasting Drivers and Weights
        • 1.6.2.3.2 Scenario Framework (2025-2033)
        • 1.6.2.3.3 Factor-Based Impact Assessment
    • 1.6.3 Estimation Process: Pharmacy Type Split By Catchment Area
      • 1.6.3.1 Data Sources
      • 1.6.3.2 Estimation Process
    • 1.6.4 Estimation Process: Pharmacy Type Split By Product Form
    • 1.6.5 Company-Level Metric's Estimation
      • 1.6.5.1 Financial Performance
        • 1.6.5.1.1 2024 Revenue & EBITDA (Pharmacy-Only)
        • 1.6.5.1.2 5-Year Forecast of Revenue & EBITDA
        • 1.6.5.1.3 Balance Sheet Health Indicators
      • 1.6.5.2 Volumes & Operations
        • 1.6.5.2.1 2024 Total Prescriptions; 5-Year Rx Forecast
        • 1.6.5.2.2 % Fulfilled via Central Fill; Volumes Split by Catchment Area
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations
  • 1.9 Research Objectives
    • 1.9.1 Objective - 1
    • 1.9.2 Objective - 2
    • 1.9.3 Objective - 3

Chapter 2. Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Outlook - I
  • 2.3 Segment Outlook- II
  • 2.4 Competitive Scenario

Chapter 3. U.S. Pharmacy Market - Industry Outlook

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Related Market Outlook
      • 3.1.2.1 U.S. pharmacy benefit management market
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Increasing prevalence of chronic diseases
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Expanding health insurance coverage
      • 3.2.1.4 Increasing demand for specialty drugs
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Product recalls and lawsuits
      • 3.2.2.2 Lack of trained staff
    • 3.2.3 Market Opportunity Analysis
    • 3.2.4 Market Challange Analysis
  • 3.3 Regulatory Scenario & Reimbursement Outlook
    • 3.3.1 Regulatory Scenario
    • 3.3.2 Reimbursement Scenario
  • 3.4 Business Environment Analysis Tools
    • 3.4.1 Porter's Five Forces Analysis
    • 3.4.2 Pestle Analysis

Chapter 4. U.S. Pharmacy Market: Product Type Estimates & Trend Analysis

  • 4.1 U.S. Pharmacy Market: Product Type Segment Dashboard
  • 4.2 Product Type Movement & Market Share Analysis, 2024 & 2033
  • 4.3 U.S. Pharmacy Market Size & Forecast and Forecasts, By Product Type (USD Billion)
    • 4.3.1 Prescription
      • 4.3.1.1 Prescription market, 2021-2033 (USD Billion)
    • 4.3.2 Over-the-Counter (OTC)
      • 4.3.2.1 OTC market, 2021-2033 (USD Billion)

Chapter 5. U.S. Pharmacy Market: Type Estimates & Trend Analysis

  • 5.1 U.S. Pharmacy Market: Type Segment Dashboard
  • 5.2 Type Movement & Market Share Analysis, 2024 & 2033
  • 5.3 U.S. Pharmacy Market Size & Forecast and Forecasts, By Type, 2021 - 2033 (USD Billion)
  • 5.4 U.S. Pharmacy Market: Estimated Number of Pharmacies, By Type, 2021 - 2033 (Unit)
  • 5.5 U.S. Pharmacy Market: Estimated Prescription Volume, By Type, 2021 - 2033 (Million)
  • 5.6 U.S. Pharmacy Market: Estimated Prescription Volume, By Catchment Area, 2024 (%)
  • 5.7 U.S. Pharmacy Market: Estimated Prescription Volume, By Filled Prescriptions (TRx), 2024 (%)
    • 5.7.1 Retail Chains
      • 5.7.1.1 Retail chains market, 2021 - 2033 (USD Billion)
    • 5.7.2 Supermarket Pharmacies
      • 5.7.2.1 Supermarket pharmacies market, 2021 - 2033 (USD Billion)
    • 5.7.3 Health System / Hospital Pharmacy
      • 5.7.3.1 Health system / Hospital pharmacy market, 2021 - 2033 (USD Billion)
    • 5.7.4 Independent Pharmacies
      • 5.7.4.1 Independent pharmacies market, 2021 - 2033 (USD Billion)
    • 5.7.5 Mail-Order Pharmacies
      • 5.7.5.1 Mail-order pharmacy market, 2021 - 2033 (USD Billion)
    • 5.7.6 Specialty / Central Fill Pharmacies
      • 5.7.6.1 Specialty / central fill pharmacies market, 2021 - 2033 (USD Billion)
    • 5.7.7 Long-Term Care And Defense-Related Pharmacies
      • 5.7.7.1 Long-term care and defense-related pharmacies market, 2021 - 2033 (USD Billion)
    • 5.7.8 Epharmacy
      • 5.7.8.1 ePharmacy market, 2021 - 2033 (USD Billion)
    • 5.7.9 Others
      • 5.7.9.1 Others market, 2021 - 2033 (USD Billion)

Chapter 6. U.S. Pharmacy Market Competitive Analysis

  • 6.1 Company Categorization
  • 6.2 Estimated Company Market Share Analysis, 2024
    • 6.2.1 CVS Pharmacy
      • 6.2.1.1 Company Overview
      • 6.2.1.2 Financial Performance
        • 6.2.1.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
        • 6.2.1.2.2 EBITDA (%) & EBITDA Margin (2024)
        • 6.2.1.2.3 Balance sheet health metrics (2024)
      • 6.2.1.3 Volumes & Operations
        • 6.2.1.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
        • 6.2.1.3.2 % of prescriptions fulfilled via central fill (2024)
        • 6.2.1.3.3 % of prescriptions fulfilled by catchment areas (2024)
      • 6.2.1.4 Value Chain Position
        • 6.2.1.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.1.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.1.5 Central Fulfillment (if used/planned)
        • 6.2.1.5.1 Strategy
        • 6.2.1.5.2 Requirements
        • 6.2.1.5.3 Technology provider(s) and hardware/automation
        • 6.2.1.5.4 Partnerships
      • 6.2.1.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
    • 6.2.2 Walgreens Boots Alliance, Inc.
      • 6.2.2.1 Company Overview
      • 6.2.2.2 Financial Performance
        • 6.2.2.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
        • 6.2.2.2.2 EBITDA (%) & EBITDA Margin (2024)
        • 6.2.2.2.3 Balance sheet health metrics (2024)
      • 6.2.2.3 Volumes & Operations
        • 6.2.2.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
        • 6.2.2.3.2 % of prescriptions fulfilled via central fill (2024)
        • 6.2.2.3.3 % of prescriptions fulfilled by catchment areas (2024)
      • 6.2.2.4 Value Chain Position
        • 6.2.2.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.2.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.2.5 Central Fulfillment (if used/planned)
        • 6.2.2.5.1 Strategy
        • 6.2.2.5.2 Requirements
        • 6.2.2.5.3 Technology provider(s) and hardware/automation
        • 6.2.2.5.4 Partnerships
      • 6.2.2.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
    • 6.2.3 Scriptco Pharmacy
      • 6.2.3.1 Company Overview
      • 6.2.3.2 Financial Performance
        • 6.2.3.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
        • 6.2.3.2.2 EBITDA (%) & EBITDA Margin (2024)
        • 6.2.3.2.3 Balance sheet health metrics (2024)
      • 6.2.3.3 Volumes & Operations
        • 6.2.3.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
        • 6.2.3.3.2 % of prescriptions fulfilled via central fill (2024)
      • 6.2.3.4 Value Chain Position
        • 6.2.3.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.3.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.3.5 Central Fulfillment (if used/planned)
        • 6.2.3.5.1 Strategy
        • 6.2.3.5.2 Requirements
        • 6.2.3.5.3 Technology provider(s) and hardware/automation
        • 6.2.3.5.4 Partnerships
      • 6.2.3.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
    • 6.2.4 Walmart Pharmacy
      • 6.2.4.1 Company Overview
      • 6.2.4.2 Financial Performance
        • 6.2.4.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
        • 6.2.4.2.2 EBITDA (%) & EBITDA Margin (2024)
        • 6.2.4.2.3 Balance sheet health metrics (2024)
      • 6.2.4.3 Volumes & Operations
        • 6.2.4.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
        • 6.2.4.3.2 % of prescriptions fulfilled via central fill (2024)
        • 6.2.4.3.3 % of prescriptions fulfilled by catchment areas (2024)
      • 6.2.4.4 Value Chain Position
        • 6.2.4.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.4.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.4.5 Central Fulfillment (if used/planned)
        • 6.2.4.5.1 Strategy
        • 6.2.4.5.2 Requirements
        • 6.2.4.5.3 Technology provider(s) and hardware/automation
        • 6.2.4.5.4 Partnerships
      • 6.2.4.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
    • 6.2.5 Avita Pharmacy
      • 6.2.5.1 Company Overview
      • 6.2.5.2 Financial Performance
        • 6.2.5.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
        • 6.2.5.2.2 EBITDA (%) & EBITDA Margin (2024)
        • 6.2.5.2.3 Balance sheet health metrics (2024)
      • 6.2.5.3 Volumes & Operations
        • 6.2.5.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
        • 6.2.5.3.2 % of prescriptions fulfilled via central fill (2024)
      • 6.2.5.4 Value Chain Position
        • 6.2.5.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.5.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.5.5 Central Fulfillment (if used/planned)
        • 6.2.5.5.1 Strategy
        • 6.2.5.5.2 Requirements
        • 6.2.5.5.3 Technology provider(s) and hardware/automation
        • 6.2.5.5.4 Partnerships
      • 6.2.5.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
    • 6.2.6 The Kroger Co.
      • 6.2.6.1 Company Overview
      • 6.2.6.2 Financial Performance
        • 6.2.6.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
        • 6.2.6.2.2 EBITDA (%) & EBITDA Margin (2024)
        • 6.2.6.2.3 Balance sheet health metrics (2024)
      • 6.2.6.3 Volumes & Operations
        • 6.2.6.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
        • 6.2.6.3.2 % of prescriptions fulfilled via central fill (2024)
        • 6.2.6.3.3 % of prescriptions fulfilled by catchment areas (2024)
      • 6.2.6.4 Value Chain Position
        • 6.2.6.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.6.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.6.5 Central Fulfillment (if used/planned)
        • 6.2.6.5.1 Strategy
        • 6.2.6.5.2 Requirements
        • 6.2.6.5.3 Technology provider(s) and hardware/automation
        • 6.2.6.5.4 Partnerships
      • 6.2.6.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
    • 6.2.7 Albertsons Companies, Inc.
      • 6.2.7.1 Company Overview
      • 6.2.7.2 Financial Performance
        • 6.2.7.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
        • 6.2.7.2.2 EBITDA (%) & EBITDA Margin (2024)
        • 6.2.7.2.3 Balance sheet health metrics (2024)
      • 6.2.7.3 Volumes & Operations
        • 6.2.7.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
        • 6.2.7.3.2 % of prescriptions fulfilled via central fill (2024)
        • 6.2.7.3.3 % of prescriptions fulfilled by catchment areas (2024)
      • 6.2.7.4 Value Chain Position
        • 6.2.7.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.7.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.7.5 Central Fulfillment (if used/planned)
        • 6.2.7.5.1 Strategy
        • 6.2.7.5.2 Requirements
        • 6.2.7.5.3 Technology provider(s) and hardware/automation
        • 6.2.7.5.4 Partnerships
      • 6.2.7.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
    • 6.2.8 Costco Wholesale Corporation.
      • 6.2.8.1 Company Overview
      • 6.2.8.2 Financial Performance
        • 6.2.8.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
        • 6.2.8.2.2 EBITDA (%) & EBITDA Margin (2024)
        • 6.2.8.2.3 Balance sheet health metrics (2024)
      • 6.2.8.3 Volumes & Operations
        • 6.2.8.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
        • 6.2.8.3.2 % of prescriptions fulfilled via central fill (2024)
        • 6.2.8.3.3 % of prescriptions fulfilled by catchment areas (2024)
      • 6.2.8.4 Value Chain Position
        • 6.2.8.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.8.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.8.5 Central Fulfillment (if used/planned)
        • 6.2.8.5.1 Strategy
        • 6.2.8.5.2 Requirements
        • 6.2.8.5.3 Technology provider(s) and hardware/automation
        • 6.2.8.5.4 Partnerships
      • 6.2.8.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
    • 6.2.9 Sam's West, Inc.
      • 6.2.9.1 Company Overview
      • 6.2.9.2 Value Chain Position
        • 6.2.9.2.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
        • 6.2.9.2.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
      • 6.2.9.3 Central Fulfillment (if used/planned)
        • 6.2.9.3.1 Strategy
        • 6.2.9.3.2 Requirements
        • 6.2.9.3.3 Technology provider(s) and hardware/automation
        • 6.2.9.3.4 Partnerships
      • 6.2.9.4 Strategy Mapping/ Major Deals & Strategic Alliances Analysis

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 Specialty Drug Expenditures, 2016 - 2021
  • Table 4 U.S. Pharmacy Market Revenue Estimates and Forecast, By Product Type, 2021 - 2033 (USD Billion)
  • Table 5 U.S. Pharmacy Market Revenue Estimates and Forecast, By Type, 2021 - 2033 (USD Billion)
  • Table 6 U.S. Pharmacy Market: Estimated Number of Pharmacies, By Type, 2021 - 2033 (Unit)
  • Table 7 U.S. Pharmacy Market: Estimated Prescription Volume, By Type, 2021 - 2033 (Million)
  • Table 8 U.S. Pharmacy Market Revenue Estimates and Forecast, By Ownership, 2021 - 2033 (USD Billion)
  • Table 9 U.S. Pharmacy Market: Estimated Prescription Volume, By Catchment Area, 2024 (%)
  • Table 10 U.S. Pharmacy Market: Estimated Prescription Volume, By Filled Prescriptions (TRX), 2024 (%)

List of Figures

  • Fig. 1 U.S. Pharmacy Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Information Procurement
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot
  • Fig. 9 Segment Outlook-I
  • Fig. 10 Segment Outlook-II
  • Fig. 11 Competitive Scenario
  • Fig. 12 U.S. Pharmacy Market: Parent Market Outlook
  • Fig. 13 U.S. Pharmacy Market: Ancillary/Related Market Outlook
  • Fig. 14 U.S. Pharmacy Market Dynamics
  • Fig. 15 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 16 Estimated New Cancer Cases, 2024
  • Fig. 17 Estimated US Prevalence of Stroke, 2018 - 2030
  • Fig. 18 Estimated US Prevalence of Prostate Cancer, 2018 - 2030
  • Fig. 19 Estimated US Prevalence of Kidney Cancer, 2018 - 2030
  • Fig. 20 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 21 Number of Pharmacy Degrees Conferred 2018 - 2023 By Gender
  • Fig. 22 U.S. Pharmacy Market: Porter's Five Forces Analysis
  • Fig. 23 U.S. Pharmacy Market: PESTLE Analysis
  • Fig. 24 U.S. Pharmacy Market: Product Type Segment Dashboard
  • Fig. 25 U.S. Pharmacy Market: Product Type Market Share Analysis, 2024 & 2033
  • Fig. 26 Prescription Market, 2021 - 2033 (USD Billion)
  • Fig. 27 OTC Market, 2021 - 2033 (USD Billion)
  • Fig. 28 U.S. Pharmacy Market: Type Segment Dashboard
  • Fig. 29 U.S. Pharmacy Market: Type Market Share Analysis, 2024 & 2033
  • Fig. 30 Retail Pharmacy Market, 2021 - 2033 (USD Billion)
  • Fig. 31 Supermarket Pharmacies Market, 2021 - 2033 (USD Billion)
  • Fig. 32 Health System / Hospital Pharmacy Market, 2021 - 2033 (USD Billion)
  • Fig. 33 Independent Pharmacies Market, 2021 - 2033 (USD Billion)
  • Fig. 34 Mail-Order Pharmacy Market, 2021 - 2033 (USD Billion)
  • Fig. 35 Specialty / Central Fill Pharmacies Market, 2021 - 2033 (USD Billion)
  • Fig. 36 Long-Term Care and Defense-Related Pharmacies Market, 2021 - 2033 (USD Billion)
  • Fig. 37 E-pharmacy Market, 2021 - 2033 (USD Billion)
  • Fig. 38 Others Market, 2021 - 2033 (USD Billion)
  • Fig. 39 U.S. Pharmacy Market: Ownership Segment Dashboard
  • Fig. 40 U.S. Pharmacy Market: Ownership Market Share Analysis, 2024 & 2033
  • Fig. 41 Chain Pharmacy Market, 2021 - 2033 (USD Billion)
  • Fig. 42 Independent Pharmacy Market, 2021 - 2033 (USD Billion)
  • Fig. 43 Key Company Categorization
  • Fig. 44 Estimated Company Market Share Analysis, 2024